Xeris Biopharma Holdings, Inc.
XERSDrugs in Pipeline
12
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
6wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
Glucagon
Diabetes Mellitus, Type 1
G-Pen (glucagon injection)
Hypoglycemia
G-Pen
Insulin Hypoglycemia
Lilly Glucagon
Insulin Hypoglycemia
Glucagon RTU
Hyperinsulinemic Hypoglycemia
Glucagon RTU Injection With Insulin Pump Reduction
Hypoglycemia
G-Pen Mini™ (glucagon injection)
Hypoglycemia
PRAM9
Diabetes Mellitus, Type 1
G-Pen(TM) 1 mg
Hypoglycemia
Novo Nordisk GlucaGen®
Hypoglycemia
levothyroxine sodium
Hypothyroidism
G-Pump™ (glucagon infusion)
Hypoglycemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Glucagon | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
G-Pen (glucagon injection) | Phase 3 | Hypoglycemia | - | - |
G-Pen | Phase 3 | Insulin Hypoglycemia | - | - |
Lilly Glucagon | Phase 3 | Insulin Hypoglycemia | - | - |
Glucagon RTU | Phase 2 | Hyperinsulinemic Hypoglycemia | - | - |
Glucagon RTU Injection With Insulin Pump Reduction | Phase 2 | Hypoglycemia | - | - |
G-Pen Mini™ (glucagon injection) | Phase 2 | Hypoglycemia | - | - |
PRAM9 | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
G-Pen(TM) 1 mg | Phase 2 | Hypoglycemia | - | - |
Novo Nordisk GlucaGen® | Phase 2 | Hypoglycemia | - | - |
levothyroxine sodium | Phase 2 | Hypothyroidism | - | - |
G-Pump™ (glucagon infusion) | Phase 2 | Hypoglycemia | - | - |